Navigation Links
Niacin Causes Serious Unexpected Side-effects, but no Worthwhile Benefits, for Patients who are at Increased Risk of Heart Attacks and Strokes
Date:3/9/2013

SAN FRANCISCO, March 9, 2013 /PRNewswire/ --

Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having a heart attack or stroke, Oxford University scientists leading the HPS2-THRIVE study have revealed at the ACC conference in San Francisco today.

In addition, the researchers report that the use of ER niacin causes a significant number of different types of serious side effect. Some of these side effects were already known to be caused by niacin, but some of them were unexpected.  

Niacin has been used for many years to modify cholesterol levels in people at high risk of heart attacks and strokes. It is particularly widely used in the United States, although there is limited evidence that it reduces the risk of cardiovascular outcomes (e.g. heart attacks and strokes), especially when added to current cholesterol-lowering therapy. Flushing is a common side effect that reduces compliance with niacin therapy. In HPS2-THRIVE, the ER niacin was combined with a new drug called laropiprant (which is a prostaglandin receptor blocker) in order to reduce problems due to flushing.

Over 25,000 patients with pre-existing cardiovascular disease from the UK, Scandinavia and China were recruited into HPS2-THRIVE. They were all given simvastatin (plus, when required, another cholesterol-lowering drug called ezetimibe) as background treatment to reduce their initial cholesterol level. They were then assigned at random to receive either the ER niacin with laropiprant or a dummy (placebo) treatment for about 4 years. HPS2-THRIVE is, by far, the biggest study of niacin ever undertaken. The use of randomised treatment assignment, and the large size and long duration, make the findings very reliable.

The primary aim of the HPS2-THRIVE trial was to find out whether adding niacin to currently standard
'/>"/>

SOURCE CTSU Oxford University
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Leading Cardiology Experts Advice on Dietary Supplement Niacins: Make Informed Choices at the Shelf and Scan the Label for Nicotinic Acid
2. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
3. Leading Cardiologist Dispels the Myths about Dietary Supplement Niacin
4. First, do no harm: Study finds danger in standard treatment for a serious lung disease
5. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
6. Dallas Car Wreck Lawyer Discusses Serious Consequences of Driving While Under the Influence of Drugs
7. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
8. Da Vinci Robot May Cause Serious Complications for Patients Receiving Hysterectomies and Other Procedures, Reports Surgical News
9. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
10. Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
11. Lillys Team Solutions and Solutions for Wellness Resources for Serious Mental Illness Added to SAMHSAs Distinguished National Registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... New England Journal of Medicine ( NEJM ) ... the investigational oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib ... small lymphocytic lymphoma (SLL). Ibrutinib was shown to be ... SLL, even in patients who were at high-risk due ...
(Date:6/19/2013)... , June 19, 2013 The Physician-Patient Alliance for ... fatigue. The need to urgently address this issue ... Sentinel Event Alert #50 , "Medical device alarm safety in ... between January 2008 and June 2012, there were 98 alarm ... in death (82%) , 13 resulted in permanent loss ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3
... LONG BRANCH, N.J., March 1, 2011 Pharma ChemOutsourcing today ... member companies of the USA,s various state biotechnology associations to ... would like to attend the September 12-15 show in New ... of hundreds of successful biotechnology companies over the past 12 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced that ... Citi 2011 Global Health Care Conference on Thursday, March ... New York Hotel in New York City. Cowen and ... 2011 at 4:45 p.m. Eastern Time at The Boston Marriott ...
Cached Medicine Technology:Pharma ChemOutsourcing Targets BioNJ, PA Bio, MassBio, BayBio, SoCalBio, and NY Biotechnology Association Member Companies for September 2011 Show in New Jersey 2Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2
(Date:6/19/2013)... 2013 Chrysler made news recently when it ... 2.7 million Jeeps. The Jeep models in question are the ... according to the NHTSA are vulnerable to fire and explosion ... models are rear-mounted and have been alleged to catch fire ... Grand Cherokee with 32 rear-end crashes, which resulted in 44 ...
(Date:6/19/2013)... 19, 2013 Amber Roberson with ... Benefits, LLC, Native Care Health, LLC and Medcase, ... Health Underwriters’ (NAHU) new professional development course on ... This continuing education course for agents has been ... receive eleven education credits from the Missouri Department ...
(Date:6/19/2013)... New York, New York (PRWEB) June 19, 2013 ... involving pancreatitis and pancreatic cancer continue to mount in ... the U.S. Food & Drug Administration (FDA) recently held ... other diabetes drugs known as incretin mimetics. According ... may seek additional data from the makers of Januvia ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... has increased its health budget by over 30 percent ... a new medical college//. ,"In a bid to ... medical education department budget to about Rs.1.52 billion. This ... billion," an official said. ,"The government not ...
... the June Journal of the American Society of Nephrology ... for chronic renal failure//. ,"Our results confirm an ... as an important causative factor in kidney disease," comments ... of the new study. ,Dr. Ejerblad and colleagues ...
... According to a new study by New York University School ... New York City are severely infected// with hepatitis B virus. ... the liver gets inflamed and can ultimately lead to cirrhosis ... 12 issue of Morbidity and Mortality Weekly, published by the ...
... new study, oral and intravenous antiviral drug may be ... ,Shingles, which is caused by varicella-zoster virus, is a ... at the University of Colorado and Health Sciences Center ... three women with moderate to severe pain following shingles. ...
... Middle school students have expressed a high degree of comfort ... schools are safer// , and make the students feel wanted. ... other schools. Psychologists from UCLA and UC ... than 70 sixth-grade classrooms in 11 Los Angeles public middle ...
... which is a severe form of food poisoning, now has ... team of researchers working at the University of Bristol//. ... researchers have narrowed down on a particular antibiotic called fosfomycin, ... effective in the laboratory, this drug has never been considered ...
Cached Medicine News:Health News:Kidney Failure three times pronounced with obesity 2Health News:Asian American Community Prone To Hepatitis B infection 2Health News:Asian American Community Prone To Hepatitis B infection 3Health News:Comfort Level, Maximum in Ethnically Diverse Schools 2Health News:Comfort Level, Maximum in Ethnically Diverse Schools 3
Indications For Usage: , Nasal surgery. , Ophthalmic surgery. , Facial surgery. , T&A surgery. ...
The Cuffed Endoflex endotracheal tube had a murphy eye, high volume, low pressure cuff., ,Endoflex endotracheal tubes are individual packaged in sterilized pouches, 10 units per box, 10 boxes pe...
... The new Level 1 H-1200 Fast Flow ... builds on the benefits of the existing Level ... Level 1 H-1200 Fast Flow Fluid Warmer incorporates ... clamping capability, while continuing to deliver warm fluids ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
Medicine Products: